Results 21 to 30 of about 552 (131)

Experience with olokizumab in the treatment of polymyalgia rheumatica and giant cell arteritis: A series of cases

Научно-практическая ревматология
Glucocorticoids are the basis for the treatment of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR), however, their long-term use is associated with a number of well-known side effects.
Alexey D. Meshkov, Alexey L. Maslyansky, Nikolay M. Bulanov, Ekaterina E. Filatova, Pavel I. Novikov, Anton V. Naumov, Olga N. Tkacheva   +6 more
doaj   +2 more sources

Prospects of using olokizumab in the treatment of polymyalgia rheumatica: preliminary analysis data

Российский журнал гериатрической медицины
BACKGROUND. Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are diseases that develop in people over 50 years of age and often require long—term glucocorticoid (GC) therapy, which is associated with a high risk of side effects. In this regard,
A. D. Meshkov, A. L. Maslyansky, A. V. Torgashina, I. O. Smitienko, P. I. Novikov, E. P. Ilivanova, A. L. Chudinov, E. G. Zotkin, A. V. Naumov, O. N. Tkacheva   +9 more
doaj   +2 more sources

Use of olokizumab, a direct interleukin 6 inhibitor, in the treatment of rheumatoid arthritis: real-world evidence

Современная ревматология
Objective: To study the efficacy and safety of olokizumab (OKZ) in patients with rheumatoid arthritis (RA) in real-life clinical practice.Material and methods. The observational program was conducted in 73 centers across Russia from Dec 1, 2022 to Jan 31,
P. A. Shesternya, A. I. Zagrebneva, O. V. Antipova, Yu. V. Arbuzova, I. G. Bannikova, L. V. Belozertseva, E. A. Bogdanova, S. A. Bykova, E. A. Vasilenko, I. B. Vinogradova, S. Yu. Davidyan, O. E. Epifanova, E. V. Zemerova, M. V. Zlobin, L. V. Ivanova, N. A. Ilyina, L. V. Ilyushina, E. P. Klyuchnikova, A. V. Makevnina, E. R. Myasoutova, E. E. Nakonechnaya, A. B. Pavlova, T. V. Plaksina, A. V. Rybin, T. S. Salnikova, L. V. Solodovnikova, A. V. Fedorova, I. A. Cherencova, E. V. Jakovleva, S. P. Yakupova, E. N. Alekseev, A. M. Lila   +31 more
doaj   +2 more sources

Olokizumab for treatment of rheumatoid arthritis [PDF]

Clinical pharmacology and therapy, 2021
Olokizumab is a new humanized monoclonal antibody targeting IL-6 that is approved for treatment of patients with moderately severe or severe active rheumatoid arthritis despite therapy with methotrexate and other conventional diseasemodifying antirheumatic drugs or biologic agents.
S. Moiseev, P. Novikov, N. Chebotareva, S. Gulyaev, N. Bulanov, T. Schevtsova, E. Shchegoleva   +6 more
openaire   +1 more source

Efficacy of olocizumab in treatment of COVID-19 patients

Acta Biomedica Scientifica, 2022
Background. Production of pro-inflammatory cytokines including interleukin 6 (IL-6) is activated in COVID-19. Using olokizumab which inhibits IL-6 production in treatment of COVID-19 is pathogenetically justified.The aim.
T. V. Goma, A. N. Kalyagin, O. V. Ryzhkova, N. S. Soloveva   +3 more
doaj   +1 more source

Evaluation of the economic effect of biological therapy in patients with severe COVID-19 and cytokine storm

Фармакоэкономика, 2021
Aim. The study aimed to assess the economic effect of biological therapy with anti-interleukin (IL)-6 drugs: tocilizumab, olokizumab, and levilimab in patients with severe COVID-19 and cytokine storm.Materials and Methods.
M. Yu. Frolov, A. S. Salasyuk, V. A. Rogov   +2 more
doaj   +1 more source

Management of patients with rheumatoid arthritis in real clinical practice: Switching from interleukin 6 receptor inhibitors to interleukin 6 inhibitor (olokizumab)

Научно-практическая ревматология, 2023
Aim. Switching to another biologic with the same mode of action provides greater opportunity for long-term management of patients with rheumatoid arthritis (RA).
A. A. Baranov, I. B. Vinogradova, O. N. Anoshenkova, O. V. Antipova, E. A. Bogdanova, Y. Y. Grabovetskaya, E. P. Ilivanova, A. N. Kalyagin, I. N. Kushnir, N. A. Lapkina, M. V. Mokrousova, O. B. Nesmeyanova, N. M. Nikitina, P. A. Shesternya, N. V. Yudina, E. Feist, E. L. Nasonov   +16 more
doaj   +1 more source

Interleukin 6 Inhibition in Rheumatoid Arthritis: Highlight on Olokizumab

Rheumatology, 2023
Rheumatoid arthritis (RA) is a chronic immunoinflammatory rheumatic disease, which manifests as progressive destruction of joints, systemic inflammation of visceral organs and a wide range of comorbidities associated with chronic inflammation. Among the cytokines involved in the pathogenesis of RA and certain other immunoinflammatory rheumatic diseases,
Evgeny Nasonov, Eugen Feist
openaire   +1 more source

The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6)

Научно-практическая ревматология, 2022
Rheumatoid arthritis (RA) is a chronic immune-mediated rheumatic diseases (IMRDs) manifested with progressive destruction of joints, systemic inflammation of visceral organs and a wide range of co-morbidities associated with chronic inflammation.
E. L. Nasonov, E. Feist
doaj   +1 more source

Safety profile assessment of drug products used for the pathogenetic treatment of COVID19 [PDF]

Клиническая микробиология и антимикробная химиотерапия, 2021
Objective. To review and summarize literature data in studies of safety of the drug products used for the pathogenetic treatment of COVID-19. Materials and Methods.
Syraeva G.I., Mishinova S.A., Kolbin A.S., Eremenko E.O.   +3 more
doaj   +1 more source